to Block the Effects of Growth & Proliferation
In normal, healthy development, cells divide rapidly and proliferate to form the tissues and organs of the human body. Once these cells terminally differentiate, they are committed to a particular cell state and lose the ability to proliferate.
Normal stem cells transition through proliferative, plastic cell states as they mature. Hijacked developmental pathways push cells back into highly proliferative, plastic cell states causing a range of diseases.*
The plastic states of cancer cells are associated with the most aggressive, metastatic, and drug-resistant tumors. By targeting the drivers that lock cancer cells in an altered cell state, we can revert the tumor cells back to their normal cell state and inhibit their growth and proliferation.
Cell plasticity is also a key factor in inflammatory diseases. The ability (or inability) of immune cells to adapt and change cell state can play a key role in driving disease.
for Rapid Drug Discovery & Development
We have built a proprietary platform called AURIGIN that we are leveraging for the rapid discovery and development of therapies targeting cell-state plasticity.
AURIGIN is a proprietary platform that integrates our developmental biology expertise with AI Machine Learning algorithms. It includes a database of single cell genomics data that allows it to compare normal cell states to diseased cell states. The power of AURIGIN is its ability to harnesses novel insights into disease biology and generate validated targets, identify optimized model systems for early program de-risking, and identify biomarkers for effective patient selection.
We have fostered a culture that encourages our team to be curious, to think strategically and creatively, and to push the limits of science. We honor diversity and individuality, and are united by a single commitment to serve the patients and families who need new treatments.
Auron Therapeutics Announces Poster Presentation at 2025 AACR Annual Meeting
Newton, MA, March 26, 2025 – Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced that the Company will present updated preclinical data from its lead program, AUTX-703, during a poster session at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
